Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit https://www.kusajili.fr:443/Trial/fTP6m83t7E-n8Bo20G744g%24a-prospective-multicenter-randomized-open-label-active-controlled-two-parallel-groups-phase-3-study-to-compare-the-efficacy-and
I have read and accept the terms of use of the site and the Privacy Policy
Send your message